Company intelligence / Profile preview

Shinlon

Ownership: Private
Development stage: Commercial

Overview

Shinlon (Taiwan) Co., Ltd. is a pharmaceutical company and a key subsidiary of the Sinphar Group, specializing in the manufacturing and distribution of pharmaceutical products. The company operates as a contract manufacturing organization (CMO) and a developer of generic drugs, focusing on high-quality production standards such as PIC/S GMP. Shinlon's portfolio includes a wide range of therapeutic products, including cardiovascular, metabolic, and respiratory medications. As part of the Sinphar Group, it leverages extensive regional infrastructure to serve both the domestic Taiwanese market and international clients.

Modalities: Small molecule
Industry: Biotech

Drug pipeline

2 assets

蓉憶記

Commercial

Indications: Memory/cognitive support (health supplement)

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Shinlon.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shinlon.

Explore the full profile